Posts By :

areisli

Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study

Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer

Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va. (October 19, 2020) – Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of Tsc in COVID-19 Patients

Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of Tsc in COVID-19 Patients 2560 1707 Diffusion Pharmaceuticals Inc.

Dosing expected to begin in Q2 2020 with first data in Q3 2020 Trial expected…

Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed Tsc COVID-19 Clinical Trial Program

Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed Tsc COVID-19 Clinical Trial Program 2560 1707 Diffusion Pharmaceuticals Inc.

First U.S. study to feature double-blinded, controlled, randomized trial design with safety and oxygenation endpoints…

Diffusion Pharmaceuticals Expands Clinical Trial Program of Tsc for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases

Diffusion Pharmaceuticals Expands Clinical Trial Program of Tsc for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases 2560 1707 Diffusion Pharmaceuticals Inc.

Planned study features noted principal investigator, regulatory flexibility, and immediate availability of patients CHARLOTTESVILLE, Va.,…

Back to top